Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 283 | Poster Presentation | Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 376 | Poster Presentation | A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 805 | Poster Presentation | Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | Mark Lythgoe, MBBS, MRPharmS; Justin Stebbing; Emily Pickford; Axel Glasmacher; Marsilio Adriani, PhD; Gayle L. Fyvie; Adam Frampton; Alex Stevenson; Jonathan Krell, PhD, MRCP, MBChB, BSc; | In-Progress Clinical Trials | Clinical study; Clinical trial; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR |
